SRx Health Solutions (SRXH) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition creates a global health and wellness company, leveraging pharmaceutical expertise and distribution to expand into veterinary medicine and pet healthcare, complementing the existing Halo pet food portfolio.

• Entry into animal pharmaceuticals targets a key growth area in the pet care industry, supporting ongoing momentum and aligning with the vision to become a leading global health and wellness company for both humans and pets.

• SRx Health brings a leading specialty pharmacy network in Canada, complementing the acquirer's consumer brand and expanding reach.

• The combined entity aims to defray public company costs and reinvest savings into brand growth.

• Both companies will leverage each other's geographic strengths for cross-border expansion, especially into the US and EU markets.

Financial terms and conditions

• The acquisition is an all-stock transaction valued at approximately $125 million.

• Post-merger, shares outstanding will be about 23 million, with combined net debt just under $21 million.

• Pro forma ownership will be 75% insiders and 25% free float.

Synergies and expected cost savings

• Immediate synergy savings estimated at $1.5–$1.7 million, with potential to exceed $2 million as integration progresses.

• Cost savings from reduced public company expenses and operational efficiencies.